Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 4/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.50 |
| ▸ | CDC42BPB | Q9Y5S2 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | PIM2 | Q9P1W9 | 10/20 | 0.46 |
| ▸ | PIM3 | Q86V86 | 8/20 | 0.46 |
| ▸ | PIM1 | P11309 | 8/20 | 0.46 |
| ▸ | PBK | Q96KB5 | 1/20 | 0.44 |
| ▸ | CDC42BPA | Q5VT25 | 1/20 | 0.43 |
| ▸ | AKT2 | P31751 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13354904 | 1.00 | ROCK2 (0.50) | ROCK2ROCK1CDC42BPBMAPTPIM2 | |
| SCHEMBL14216365 | 1.00 | ROCK2 (0.50) | ROCK2ROCK1CDC42BPBMAPTPIM2 | |
| SCHEMBL11908053 | 0.91 | PIM2 (0.56) | ROCK2ROCK1CDC42BPBPIM2PIM3 | |
| SCHEMBL11906992 | 0.91 | PIM2 (0.56) | ROCK2ROCK1CDC42BPBPIM2PIM3 | |
| SCHEMBL11906822 | 0.90 | MAPT (0.54) | ROCK2ROCK1CDC42BPBMAPTPIM2 | |
| SCHEMBL11907206 | 0.85 | ROCK1 (0.52) | ROCK2ROCK1CDC42BPBMAPTPIM2 | |
| SCHEMBL11906623 | 0.83 | MAPT (0.47) | MAPTPIM2PIM3PIM1 | |
| SCHEMBL20189967 | 0.83 | MAPT (0.54) | ROCK2ROCK1CDC42BPBMAPTPIM2 | |
| SCHEMBL16525705 | 0.83 | ROCK2 (0.49) | ROCK2ROCK1CDC42BPBMAPTPIM2 | |
| SCHEMBL16525708 | 0.83 | ROCK2 (0.49) | ROCK2ROCK1CDC42BPBMAPTPIM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2078004-B1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8318735-B2 | 2-aminothiazole-4-carboxylic amides as protein kinase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2012-11-27 | — | — | US | disclosed |
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MERCK SHARP & DOHME LLC | 2010-05-27 | — | — | US | disclosed |
| WO-2008054749-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | SCHERING CORPORATION (US) | 2008-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130465-A1 | 2-AMINOTHIAZOLE-4-CARBOXYLIC AMIDES AS PROTEIN KINASE INHIBITORS | MAPK15, CDK15, MAP3K15 | ROCK2 794/4885ROCK1 1328/4885CDC42BPB 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.